FORT LAUDERDALE, Fla.–(BUSINESS WIRE)–Anju Software has announced that Steve Rosenberg, an industry leader and innovator in developing and deploying patient-centric clinical trial technologies, has joined the company’s Board of Directors. Rosenberg also formerly led Oracle’s clinical software business.
Rosenberg brings a real-world clinical study perspective that will help align the strengths of Anju’s business segments with the industry’s continuing and evolving needs. These include improving patient engagement and diversity, providing access to more real-world data, and managing complexities with Decentralized Clinical Trials (DCTs).
“Anju has a strong modern technology platform and significant experience in working with a wide range of Pharma and CROs globally,” added Rosenberg. ” I look forward to helping Anju develop new solutions that will help optimize how and where to conduct trials using insights from data that is collected and analyzed.”
Rosenberg is a current board member at uMotif and recently accepted a role as their new CEO. uMotif is an eClinical platform for capturing patient-centric data in clinical trials. He has a more than four-decade career in positions where he has helped shape clinical study technology development, including cloud-based solutions with a more integrated approach to patient-centric trial management.
Rosenberg designed the industry groundbreaking integrated clinical technology suite at Phase Forward, which Oracle acquired in 2010. Soon after, he led the growth of Oracle’s Health Sciences business, where he served most recently as its Senior Vice President and General Manager. Rosenberg is also a co-founder of The One By One project, a non-profit that helps people in need in the Boston area.
About Anju Software
Anju Software provides an adaptive platform for clinical trials, medical affairs, and a newly designed, state-of-the-art clinical content and data repository. Its AI-based analytical solution, combined with data and application integration capabilities, serves the worldwide pharmaceutical, biotech, and contract research organization markets.